Significant worsening of physical and mental symptoms of Parkinson disease was shown in a meta-analysis of diverse patients during the COVID-19 pandemic, with those of lower-income countries shown to be exceptionally vulnerable.
A high prevalence of physical and mental worsening of Parkinson disease (PD) was shown during the COVID-19 pandemic, in which socioeconomic status may significantly mediate risk. Results were published this week in the Annals of Clinical and Translational Neurology.
As COVID-19 has contributed to decreased accessibility of care and feelings of anxiety, isolation, and insecurity among patients with chronic disabilities worldwide, researchers note that those with PD are especially vulnerable to pandemic-related declines in health.
Prior research has found that patients with PD are already at greater risk of mood-related disorders, with the negative effects of the pandemic potentially increasing risks of adverse physical and mental well-being outcomes.
“There is a need to identify subgroups of patients with PD that may require more attention and support. It is currently not clear if biological sex, race and ethnicity, nationality, and socioeconomic status influence patients’ responses to the pandemic,” said the study authors. “These factors may also not be adequately captured by single studies or in specific populations.”
They conducted a systematic review and meta-analysis to assess the impact of the COVID-19 pandemic on patients with PD without COVID-19 infection. Studies published between 2020 and 2022 from the Medline and Embase databases were examined for the review, with random-effects pooling of estimates and meta-regression utilized to evaluate worsening of symptoms, including physical activity, exercise (either aerobic or resistance training), PD-related variables, balance, mood, depression, anxiety, cognition, and sleep.
Subgroup analyses were conducted to explore the effects of study characteristics and patient demographics on the study outcomes. A total of 27 studies consisting of 13,878 patients with PD from North/South America, Europe, Asia, and Africa were included in the analysis.
Findings showed an overall high prevalence of decreased physical activity and exercise, and worsening of motor and neuropsychiatric symptoms (17%–56%). The subgroup analyses further showed several factors to be associated with greater burden of these effects:
Researchers concluded that the study findings can help guide planning and optimize policy guidelines for pandemic preparedness. “Specific measures to address at-risk subsets of PD (especially those from low-income locations) will ameliorate the physical and mental burden associated with current and future pandemics,” they added.
Reference
Mai AS, Yong JH, Tan BJW, Xiao B, Tan EK. Impact of COVID-19 pandemic on patients with Parkinson’s disease: A meta-analysis of 13,878 patients. Ann Clin Transl Neurol. Published online September 6, 2022. doi:10.1002/acn3.51616
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
2 Commerce Drive
Cranbury, NJ 08512